Idiopathic Pulmonary Fibrosis
Conditions
Brief summary
This study is a phase 1 single dose escalation study of SHR-1906 in healthy subjects. The purpose of the study is to evaluate the safety, tolerability and pharmacokinetics of SHR-1906 in healthy subjects.
Interventions
DRUGSHR-1906；Placebo
Drug: SHR-1906 IV, single dose Drug: Placebo IV, single dose
Sponsors
Guangdong Hengrui Pharmaceutical Co., Ltd
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)
Intervention model description
SHR-1906 compared with placebo
Eligibility
Sex/Gender
ALL
Age
18 Years to 55 Years
Healthy volunteers
Yes
Inclusion criteria
1. Ability to understand the trial procedures and possible adverse events, volunteers to participate in the trial, and provides written informed consent, be able to comply with all the requirements and able to complete the study. 2. Male or female aged between 18 years and 55 years (inclusive) at the date of signed consent form. 3. Total body weight ≥ 45 kg. 4. No clinically significant abnormalities in medical history, general physical examination, vital signs, laboratory tests (hematology, urinalysis, blood chemistry, coagulation function and thyroid function) and ECG at the investigator's discretion during screening and baseline 5. Men and women of childbearing potential (WOCBP) must agree to take effective contraceptive methods
Exclusion criteria
1. History of serious cardiovascular, liver, kidney, digestive tract, psychiatric, hematology, metabolic disorders, primary immunodeficiency disease or acquired immune deficiency syndrome, or organ transplantation. 2. Severe infections, injuries or major surgeries (as determined by the investigator) within 6 months prior to screening, or plan to do any surgery during the trial. 3. Positive testing for human immunodeficiency virus (HIV-Ab), or hepatitis B surface antigen (HBsAg), or TP-Ab , or hepatitis C antibodies (HCV-Ab). 4. Screening/baseline systolic blood pressure (BP) ≥140 mmHg or ≤90 mmHg; diastolic BP ≥90 mmHg or \<60 mmHg on a single measurement 5. Positive urine drug screening at baseline; 6. Use of any medicine within 1 monthes (including any prescription, or over-the-counter medicine, herbal remedy or nutritional supplement, except for vitamins and occasional use of acetaminophen with recommended dose), or within 5 half-lives of any drugs whichever is longer prior to dosing, or plan to use any medicine during the trial. 7. Participation in clinical trials of other investigational drugs or medical devices within 3 months prior to screening or within 5 half-lives of any drugs during screening visit, or in the follow-up period of a clinical study whichever is longer (according to the date of signed consent form) which is defined as having consented and used other investigational drugs (including placebo) or trial medical devices. 8. Blood donation or loss of ≥ 400 mL of blood within 1 months; or received blood or blood products within 2 months prior to screening. 9. Any other circumstances that, in the investigator's judgment, may increase the risk associated with the subject's participation in and completion of the study or could preclude the evaluation of the subject's response. 10. Researchers and relevant staff of the research center or other persons directly involved in the implementation of the program.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Adverse events | Start of Treatment to end of study (approximately 10 weeks) | Incidence and severity of adverse events |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Pharmacokinetics-AUC0-inf | Start of Treatment to end of study (approximately 10 weeks) | Area under the concentration-time curve from time 0 to infinity after SHR-1906 administration |
| Pharmacokinetics-Tmax | Start of Treatment to end of study (approximately 10 weeks) | Time to Cmax of SHR-1906 |
| Pharmacokinetics-Cmax | Start of Treatment to end of study (approximately 10 weeks) | Maximum observed concentration of SHR-1906 |
| Pharmacokinetics-AUC0-last | Start of Treatment to end of study (approximately 10 weeks) | Area under the concentration-time curve from time 0 to last time point after SHR-1906 administration |
| Pharmacokinetics-V | Start of Treatment to end of study (approximately 10 weeks) | Volume of distribution during terminal phase of SHR-1906 |
| Pharmacokinetics-t1/2 | Start of Treatment to end of study (approximately 10 weeks) | Terminal elimination half-life of SHR-1906 |
| Anti-Drug antibody | Start of Treatment to end of study (approximately 10 weeks) | The percentage of subjects with positive ADA titers over time for SHR-1906 |
| Pharmacokinetics-CL | Start of Treatment to end of study (approximately 10 weeks) | Clearance of SHR-1906 |
Countries
China
Outcome results
None listed